Halozyme to Present at the Jefferies 2010 Global Life Sciences Conference on June 8

SAN DIEGO, June 1, 2010 /PRNewswire via COMTEX/ --Halozyme Therapeutics, Inc. (Nasdaq: HALO), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix, today announced that management will participate in the Jefferies 2010 Global Life Sciences Conference to be held June 8-11, 2010 in New York City. Dr. Jonathan Lim, M.D., president and CEO, is scheduled to present an overview of Halozyme and its product development pipeline on Tuesday, June 8 at 3:00 p.m. EDT (12:00 p.m. PDT).

(Logo: http://www.newscom.com/cgi-bin/prnh/20100302/LA63139LOGO)

To listen to the live webcast or a replay of the presentation, please visit the Investor Relations section of the company's Web site at https://www.halozyme.com. The replay will be available for 90 days after the event.

About Halozyme

Halozyme Therapeutics is a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the endocrinology, oncology, dermatology and drug delivery markets. The company's product portfolio is based primarily on intellectual property covering the family of human enzymes known as hyaluronidases and additional enzymes that affect the extracellular matrix. Halozyme's Enhanze(TM) technology is a novel drug delivery platform designed to increase the absorption and dispersion of biologics. The company has key partnerships with Roche to apply Enhanze technology to Roche's biological therapeutics, including Herceptin(R) and MabThera(R), for up to 13 targets, and with Baxter BioScience to apply Enhanze technology to GAMMAGARD Liquid(R). Halozyme's Ultrafast Insulin program combines its rHuPH20 enzyme with mealtime insulins, which may produce more rapid absorption, faster action, and improved glycemic control. The product candidates in Halozyme's pipeline target multiple areas of significant unmet medical need. For more information visit https://www.halozyme.com.

    Halozyme Contact
    Robert H. Uhl
    Senior Director, Investor Relations
    (858) 704-8264
    [email protected]

SOURCE Halozyme Therapeutics, Inc.